Brain SPECT Imaging of Amphetamine-Induced Dopamine Release in Euthymic Bipolar Disorder Patients

OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combine...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of psychiatry Vol. 157; no. 7; pp. 1108 - 1114
Main Authors Anand, Amit, Verhoeff, Paul, Seneca, Nicholas, Zoghbi, Sami S., Seibyl, John P., Charney, Dennis S., Innis, Robert B.
Format Journal Article
LanguageEnglish
Published Washington, DC American Psychiatric Publishing 01.07.2000
American Psychiatric Association
Subjects
Online AccessGet full text

Cover

Loading…
Abstract OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.METHOD: Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D2 D3) receptor radiotracer iodobenzamide ([123I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg kg). Reduction in striatal [123I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.RESULTS: Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D2 receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [123I]IBZM binding.CONCLUSIONS: In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder.
AbstractList Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients. Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D(2)/D(3)) receptor radiotracer iodobenzamide ([(123)I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg/kg). Reduction in striatal [(123)I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales. Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D(2) receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [(123)I]IBZM binding. In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder.
OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.METHOD: Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D2 D3) receptor radiotracer iodobenzamide ([123I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg kg). Reduction in striatal [123I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.RESULTS: Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D2 receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [123I]IBZM binding.CONCLUSIONS: In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder.
Increased dopaminergic neutotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity.
Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.OBJECTIVEIncreased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D(2)/D(3)) receptor radiotracer iodobenzamide ([(123)I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg/kg). Reduction in striatal [(123)I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.METHODThirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D(2)/D(3)) receptor radiotracer iodobenzamide ([(123)I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg/kg). Reduction in striatal [(123)I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D(2) receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [(123)I]IBZM binding.RESULTSBipolar patients and healthy subjects did not differ in terms of mood state or striatal D(2) receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [(123)I]IBZM binding.In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder.CONCLUSIONSIn a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder.
Author Anand, Amit
Zoghbi, Sami S.
Charney, Dennis S.
Seneca, Nicholas
Seibyl, John P.
Verhoeff, Paul
Innis, Robert B.
Author_xml – sequence: 1
  givenname: Amit
  surname: Anand
  fullname: Anand, Amit
– sequence: 2
  givenname: Paul
  surname: Verhoeff
  fullname: Verhoeff, Paul
– sequence: 3
  givenname: Nicholas
  surname: Seneca
  fullname: Seneca, Nicholas
– sequence: 4
  givenname: Sami S.
  surname: Zoghbi
  fullname: Zoghbi, Sami S.
– sequence: 5
  givenname: John P.
  surname: Seibyl
  fullname: Seibyl, John P.
– sequence: 6
  givenname: Dennis S.
  surname: Charney
  fullname: Charney, Dennis S.
– sequence: 7
  givenname: Robert B.
  surname: Innis
  fullname: Innis, Robert B.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1437720$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10873919$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1v1DAQhi1URLeFX4CELEDcsvhjE8fHdrvASpWooEjcrFnHab1K7NRODv33zHYXFVUCTrZnnnfGM-8JOQoxOEJeczbnXFUfYRj8HLbDnJdqrjDG6mdkxktZFkqI-ojMGGOi0KX8eUxOct7ik0klXpBjRJXUXM8InCfwgX6_Wi2v6bqHGx9uaGzpWT_cuhF6H1yxDs1kXUMv4vAQoN9c5yA7isLVNN7e997Scz_EDhK98DmmxiV6BaN3YcwvyfMWuuxeHc5T8uPT6nr5pbj8-nm9PLssYKHFWGzkxuq6EWXZgmS1VYJBJZpaO2CV3lSYd7Vs8WZFI5QSoHGIDWhQoJTm8pR82NcdUrybXB5N77N1XQfBxSkbxYUQrNYIvn0CbuOUAv7NILAo9UIqhN79DeIlr6WuFpoh9eZATZveNWZIvod0b37vF4H3BwCyha5NEKzPjxy2wkERk3vMpphzcu0flczObLMz26DZ2F0ZZXZmo0o_UVk_4tZjGNHU7j9attc-JB9n-4fkF30Dv2Q
CODEN AJPSAO
CitedBy_id crossref_primary_10_1097_HRP_0000000000000003
crossref_primary_10_1016_j_pnpbp_2007_02_005
crossref_primary_10_1176_appi_ajp_159_10_1718
crossref_primary_10_1016_j_biopsych_2010_06_005
crossref_primary_10_1097_00004647_200303000_00004
crossref_primary_10_1111_j_1749_6632_2003_tb07095_x
crossref_primary_10_1111_j_1468_2850_2009_01166_x
crossref_primary_10_1016_j_biopsych_2005_11_006
crossref_primary_10_1300_J374v01n03_03
crossref_primary_10_1080_15332985_2011_639928
crossref_primary_10_1016_j_bpsc_2024_07_011
crossref_primary_10_1016_j_cpr_2008_04_004
crossref_primary_10_1111_bdi_12009
crossref_primary_10_1007_s11064_008_9865_8
crossref_primary_10_1007_s00441_013_1594_x
crossref_primary_10_1177_070674370104600524
crossref_primary_10_1515_REVNEURO_2009_20_2_111
crossref_primary_10_1016_j_bbr_2009_06_009
crossref_primary_10_1016_j_neuint_2013_02_001
crossref_primary_10_1586_ern_12_64
crossref_primary_10_1038_sj_mp_4002135
crossref_primary_10_1097_01_WCB_0000048520_34839_1A
crossref_primary_10_1111_jnc_13769
crossref_primary_10_1097_00001504_200105000_00011
crossref_primary_10_1016_j_neuropsychologia_2011_06_008
crossref_primary_10_1111_bdi_12251
crossref_primary_10_1016_j_neuroscience_2014_11_059
crossref_primary_10_1016_j_pscychresns_2011_04_002
crossref_primary_10_1212_01_wnl_0000341932_21961_f3
crossref_primary_10_1007_s00702_009_0198_9
crossref_primary_10_1176_ajp_2006_163_6_1112a
crossref_primary_10_1016_j_brainresrev_2008_07_006
crossref_primary_10_1001_jamapsychiatry_2017_2943
crossref_primary_10_1080_1028415X_2024_2338344
crossref_primary_10_1038_mp_2016_261
crossref_primary_10_1002_syn_20013
crossref_primary_10_1016_j_neulet_2011_05_027
crossref_primary_10_1111_j_1600_0447_2007_01058_x
crossref_primary_10_1016_j_lfs_2006_01_002
crossref_primary_10_1016_S1566_2772_02_00043_9
crossref_primary_10_1016_j_euroneuro_2022_08_006
crossref_primary_10_1016_j_jad_2004_11_009
crossref_primary_10_1111_j_1399_5618_2011_00936_x
crossref_primary_10_1192_j_eurpsy_2021_1
crossref_primary_10_1186_s12974_018_1283_5
crossref_primary_10_1016_j_jpsychires_2007_03_005
crossref_primary_10_1176_appi_ajp_2012_11101585
crossref_primary_10_1016_j_jad_2021_08_022
crossref_primary_10_1007_s00213_021_05960_2
crossref_primary_10_1007_s11011_013_9473_4
crossref_primary_10_1016_j_genhosppsych_2010_11_005
crossref_primary_10_1111_j_1399_5618_2005_00211_x
crossref_primary_10_1002_syn_20062
crossref_primary_10_1017_S146114571000101X
crossref_primary_10_1038_sj_mp_4001547
crossref_primary_10_1038_mp_2009_39
crossref_primary_10_1196_annals_1417_000
crossref_primary_10_1111_j_1399_5618_2007_00354_x
crossref_primary_10_1038_sj_mp_4001020
crossref_primary_10_1016_j_neubiorev_2006_12_001
crossref_primary_10_2116_analsci_19_67
crossref_primary_10_1073_pnas_1108416108
crossref_primary_10_1034_j_1399_5618_2001_030201_x
crossref_primary_10_1038_sj_npp_1301254
crossref_primary_10_1001_jamapsychiatry_2024_4216
crossref_primary_10_1002_syn_20238
crossref_primary_10_1007_s11064_008_9595_y
crossref_primary_10_1017_S1461145710001495
crossref_primary_10_1016_S0376_8716_00_00240_4
crossref_primary_10_1007_s00213_019_05295_z
crossref_primary_10_1016_j_psym_2012_01_005
crossref_primary_10_1176_appi_ajp_159_5_768
crossref_primary_10_1016_j_nucmedbio_2005_01_007
crossref_primary_10_1016_j_pnpbp_2003_10_015
crossref_primary_10_1046_j_1601_5215_2003_00053_x
crossref_primary_10_1111_1440_1681_13243
crossref_primary_10_1111_j_1399_5618_2010_00874_x
crossref_primary_10_1016_j_euroneuro_2008_11_002
crossref_primary_10_1016_j_childyouth_2010_03_021
crossref_primary_10_3390_biomedicines11071820
crossref_primary_10_1111_j_1399_5618_2009_00760_x
crossref_primary_10_1016_j_bbr_2019_01_006
crossref_primary_10_1016_j_brainres_2008_10_023
crossref_primary_10_1177_0891988713516540
crossref_primary_10_1176_appi_ajp_160_1_13
crossref_primary_10_1186_1471_244X_4_27
crossref_primary_10_1016_j_nbd_2010_08_005
crossref_primary_10_1146_annurev_clinpsy_2_022305_095332
crossref_primary_10_1186_1866_1955_4_19
crossref_primary_10_1007_s11682_016_9516_7
crossref_primary_10_1111_j_1399_5618_2009_00771_x
crossref_primary_10_1590_1516_4446_2013_1168
crossref_primary_10_1016_j_psc_2011_02_010
crossref_primary_10_1080_14737175_2020_1807329
crossref_primary_10_1111_j_1601_5215_2004_0061_x
crossref_primary_10_1002_ajmg_10360
crossref_primary_10_1016_j_bbr_2012_03_021
crossref_primary_10_1038_sj_npp_1300665
crossref_primary_10_1080_1029842021000022070
crossref_primary_10_1080_j_1440_1614_2006_01805_x
crossref_primary_10_1016_j_neuropharm_2011_07_025
crossref_primary_10_1038_mp_2010_3
crossref_primary_10_1111_bdi_12299
crossref_primary_10_1177_0269881106073126
crossref_primary_10_1007_s12035_019_01817_0
crossref_primary_10_1146_annurev_clinpsy_032511_143148
crossref_primary_10_1111_j_1399_5618_2004_00110_x
crossref_primary_10_1007_s10519_006_9093_4
crossref_primary_10_1016_j_ejphar_2014_05_063
crossref_primary_10_1016_S0006_3223_01_01089_7
crossref_primary_10_1177_0269881105051525
crossref_primary_10_1016_j_jad_2011_02_022
crossref_primary_10_1002_syn_10010
crossref_primary_10_1111_j_1460_9568_2004_03199_x
crossref_primary_10_1111_j_1440_1614_2006_01805_x
crossref_primary_10_1093_schbul_sbr180
crossref_primary_10_1016_j_neubiorev_2007_04_002
crossref_primary_10_1038_sj_mp_4001585
crossref_primary_10_1007_s12035_016_9933_z
crossref_primary_10_1159_000480349
crossref_primary_10_1177_0269881114523864
crossref_primary_10_1016_j_pnpbp_2006_03_016
crossref_primary_10_1002_cpp_1801
crossref_primary_10_1016_j_pbb_2010_11_004
crossref_primary_10_1080_09540260902962131
crossref_primary_10_1017_S1092852900009238
crossref_primary_10_1038_sj_npp_1301333
crossref_primary_10_1002_wps_21080
crossref_primary_10_1038_mp_2017_16
crossref_primary_10_1097_00019442_200211000_00010
crossref_primary_10_1111_j_1749_6632_2009_05146_x
crossref_primary_10_1016_j_neubiorev_2010_04_002
crossref_primary_10_1016_j_lfs_2007_11_026
crossref_primary_10_1016_S0163_8343_01_00135_9
crossref_primary_10_1586_14737175_2013_811132
crossref_primary_10_2217_npy_11_69
crossref_primary_10_1016_j_pnpbp_2008_09_017
crossref_primary_10_1016_j_jpsychires_2024_12_046
crossref_primary_10_1111_gbb_12371
crossref_primary_10_1097_WNF_0b013e31816f75bc
Cites_doi 10.1016/0969-8051(94)90087-6
10.1055/s-2007-1019521
10.2466/pr0.1962.10.3.799
10.1176/ajp.155.6.761
10.1111/j.1471-4159.1993.tb03600.x
10.1046/j.1471-4159.1998.70041768.x
10.1017/S0033291700009132
10.1176/ajp.156.9.1440
10.1192/bjp.133.5.429
10.1016/S0006-3223(99)00067-0
10.1002/syn.890100302
10.1002/syn.890070409
10.1001/archpsyc.1995.03950180057008
10.1016/0006-3223(95)00611-7
10.1073/pnas.93.17.9235
10.1007/BF00428897
10.1002/hbm.460030303
ContentType Journal Article
Copyright 2000 INIST-CNRS
Copyright American Psychiatric Association Jul 2000
Copyright_xml – notice: 2000 INIST-CNRS
– notice: Copyright American Psychiatric Association Jul 2000
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
HAWNG
HBMBR
IBDFT
K30
PAAUG
PAWHS
PAWZZ
PAXOH
PBHAV
PBQSW
PBYQZ
PCIWU
PCMID
PCZJX
PDGRG
PDWWI
PETMR
PFVGT
PGXDX
PIHIL
PISVA
PJCTQ
PJTMS
PLCHJ
PMHAD
PNQDJ
POUND
PPLAD
PQAPC
PQCAN
PQCMW
PQEME
PQHKH
PQMID
PQNCT
PQNET
PQSCT
PQSET
PSVJG
PVMQY
PZGFC
K9.
NAPCQ
7X8
DOI 10.1176/appi.ajp.157.7.1108
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Periodicals Index Online Segment 13
Periodicals Index Online Segment 14
Periodicals Index Online Segment 27
Periodicals Index Online
Primary Sources Access—Foundation Edition (Plan E) - West
Primary Sources Access (Plan D) - International
Primary Sources Access & Build (Plan A) - MEA
Primary Sources Access—Foundation Edition (Plan E) - Midwest
Primary Sources Access—Foundation Edition (Plan E) - Northeast
Primary Sources Access (Plan D) - Southeast
Primary Sources Access (Plan D) - North Central
Primary Sources Access—Foundation Edition (Plan E) - Southeast
Primary Sources Access (Plan D) - South Central
Primary Sources Access & Build (Plan A) - UK / I
Primary Sources Access (Plan D) - Canada
Primary Sources Access (Plan D) - EMEALA
Primary Sources Access—Foundation Edition (Plan E) - North Central
Primary Sources Access—Foundation Edition (Plan E) - South Central
Primary Sources Access & Build (Plan A) - International
Primary Sources Access—Foundation Edition (Plan E) - International
Primary Sources Access (Plan D) - West
Periodicals Index Online Segments 1-50
Primary Sources Access (Plan D) - APAC
Primary Sources Access (Plan D) - Midwest
Primary Sources Access (Plan D) - MEA
Primary Sources Access—Foundation Edition (Plan E) - Canada
Primary Sources Access—Foundation Edition (Plan E) - UK / I
Primary Sources Access—Foundation Edition (Plan E) - EMEALA
Primary Sources Access & Build (Plan A) - APAC
Primary Sources Access & Build (Plan A) - Canada
Primary Sources Access & Build (Plan A) - West
Primary Sources Access & Build (Plan A) - EMEALA
Primary Sources Access (Plan D) - Northeast
Primary Sources Access & Build (Plan A) - Midwest
Primary Sources Access & Build (Plan A) - North Central
Primary Sources Access & Build (Plan A) - Northeast
Primary Sources Access & Build (Plan A) - South Central
Primary Sources Access & Build (Plan A) - Southeast
Primary Sources Access (Plan D) - UK / I
Primary Sources Access—Foundation Edition (Plan E) - APAC
Primary Sources Access—Foundation Edition (Plan E) - MEA
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Periodicals Index Online Segment 14
Periodicals Index Online Segments 1-50
Periodicals Index Online Segment 27
Periodicals Index Online
Periodicals Index Online Segment 13
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE

ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1535-7228
EndPage 1114
ExternalDocumentID 56323420
10873919
1437720
10_1176_appi_ajp_157_7_1108
10.1176/appi.ajp.157.7.1108
Genre Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: NCRR NIH HHS
  grantid: RR-00125
– fundername: NIMH NIH HHS
  grantid: MH-30929
GroupedDBID ---
--Z
-DZ
-~X
.55
.GJ
0WA
1HT
1KJ
1QT
23M
2WC
3O-
4.4
53G
5GY
5RE
6J9
6TJ
7K8
85S
8R4
8R5
AAAHA
AAIKC
AAMNW
AAWTL
AAWTO
ABIVO
ABPPZ
ABZEH
ACBMB
ACGFO
ACGOD
ACHQT
ACNCT
ADBBV
ADCOW
AENEX
AETEA
AFAZI
AFFNX
AFMIJ
AFOSN
AGHSJ
AGNAY
AHJKT
AHMBA
AI.
AIZTS
ALMA_UNASSIGNED_HOLDINGS
ASUFR
BAJDF
BAWUL
BENPR
BKOMP
CS3
DIK
E3Z
EBS
EJD
EX3
F20
F5P
F8P
FA8
FJW
G0H
G8K
HF~
HZ~
J5H
L7B
MVM
N4W
N9A
NEJ
NHB
OHT
OK1
OVD
P-O
P2P
PQQKQ
Q.-
Q2X
RAY
RWL
RXW
RYA
S10
SJN
SKT
TAE
TEORI
TR2
TWZ
UHB
UKR
ULE
UPT
UQL
VH1
VVN
WH7
WHG
WOQ
WOW
X4V
X6Y
X7M
XJT
XOL
XSW
XZL
YCJ
YFH
YOC
YSK
YWH
YZZ
ZCA
ZGI
ZRR
ZXP
ZY1
~A~
~G0
AAJMC
AAYXX
ABDPE
ADMHG
CITATION
H13
08P
08R
1CY
2QL
354
41~
8F7
AAJWC
AAKAS
AAPBV
AAQQT
AAUGY
AAYJJ
ABPTK
ADZCM
AERZD
AFFDN
AKALU
BCR
BLC
GOZPB
GRPMH
IQODW
LXL
LXN
PEA
UBC
YQI
YQJ
YRY
YXB
YYQ
ZA5
ZHY
ZKB
~X8
CGR
CUY
CVF
ECM
EIF
LPU
NPM
VXZ
YIF
YIN
Z5M
HAWNG
HBMBR
IBDFT
K30
PAAUG
PAWHS
PAWZZ
PAXOH
PBHAV
PBQSW
PBYQZ
PCIWU
PCMID
PCZJX
PDGRG
PDWWI
PETMR
PFVGT
PGXDX
PIHIL
PISVA
PJCTQ
PJTMS
PLCHJ
PMHAD
PNQDJ
POUND
PPLAD
PQAPC
PQCAN
PQCMW
PQEME
PQHKH
PQMID
PQNCT
PQNET
PQSCT
PQSET
PSVJG
PVMQY
PZGFC
ADXHL
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-a492t-b3bc98d255fa308c720a62d89ea069b6b3be83f9b6c2d2772a9087ba9a7a77913
ISSN 0002-953X
IngestDate Fri Jul 11 01:45:04 EDT 2025
Fri Aug 22 03:12:36 EDT 2025
Mon Jun 30 16:06:04 EDT 2025
Wed Feb 19 01:45:11 EST 2025
Sun Oct 22 16:07:12 EDT 2023
Tue Jul 01 01:51:18 EDT 2025
Thu Apr 24 22:59:20 EDT 2025
Wed Jul 24 08:11:01 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Radionuclide study
Mood disorder
Amphetamine derivatives
Human
Dopamine
Pathophysiology
Induction
Central nervous system
Bipolar disorder
Photon
Dopaminergic transmission
Biological fixation
D2 Dopamine receptor
Amfetamine
Clinical investigation
Computer aid
Release
Brain (vertebrata)
Emission tomography
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-a492t-b3bc98d255fa308c720a62d89ea069b6b3be83f9b6c2d2772a9087ba9a7a77913
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
PMID 10873919
PQID 1518396490
PQPubID 1816671
PageCount 7
ParticipantIDs proquest_miscellaneous_71222089
proquest_journals_220459437
proquest_journals_1518396490
pubmed_primary_10873919
pascalfrancis_primary_1437720
crossref_primary_10_1176_appi_ajp_157_7_1108
crossref_citationtrail_10_1176_appi_ajp_157_7_1108
appi_journals_10_1176_appi_ajp_157_7_1108
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2000-07-01
PublicationDateYYYYMMDD 2000-07-01
PublicationDate_xml – month: 07
  year: 2000
  text: 2000-07-01
  day: 01
PublicationDecade 2000
PublicationPlace Washington, DC
PublicationPlace_xml – name: Washington, DC
– name: United States
– name: Washington, D.C
– name: Washington
PublicationTitle The American journal of psychiatry
PublicationTitleAlternate Am J Psychiatry
PublicationYear 2000
Publisher American Psychiatric Publishing
American Psychiatric Association
Publisher_xml – name: American Psychiatric Publishing
– name: American Psychiatric Association
References R1577CIHJIEJF
R1577CIHIGIAE
R1577CIHGAFIJ
R1577CIHBJCIG
R1577CIHCFHFF
R1577CIHCEDDJ
R1577CIHBGAGE
R1577CIHFJCCA
R1577CIHHGIGB
R1577CIHIJFFD
R1577CIHBFEEA
R1577CIHBCAEF
R1577CIHCAFHG
R1577CIHGGIHG
R1577CIHBADHE
R1577CIHGDEAB
R1577CIHIGHHC
R1577CIHEGBBA
References_xml – ident: R1577CIHCEDDJ
  doi: 10.1016/0969-8051(94)90087-6
– ident: R1577CIHBJCIG
– ident: R1577CIHBCAEF
  doi: 10.1055/s-2007-1019521
– ident: R1577CIHCFHFF
  doi: 10.2466/pr0.1962.10.3.799
– ident: R1577CIHJIEJF
  doi: 10.1176/ajp.155.6.761
– ident: R1577CIHBGAGE
  doi: 10.1111/j.1471-4159.1993.tb03600.x
– ident: R1577CIHCAFHG
  doi: 10.1046/j.1471-4159.1998.70041768.x
– ident: R1577CIHIJFFD
  doi: 10.1017/S0033291700009132
– ident: R1577CIHEGBBA
  doi: 10.1176/ajp.156.9.1440
– ident: R1577CIHGAFIJ
  doi: 10.1192/bjp.133.5.429
– ident: R1577CIHGDEAB
  doi: 10.1016/S0006-3223(99)00067-0
– ident: R1577CIHIGHHC
  doi: 10.1002/syn.890100302
– ident: R1577CIHIGIAE
  doi: 10.1002/syn.890070409
– ident: R1577CIHBFEEA
  doi: 10.1001/archpsyc.1995.03950180057008
– ident: R1577CIHGGIHG
  doi: 10.1016/0006-3223(95)00611-7
– ident: R1577CIHHGIGB
  doi: 10.1073/pnas.93.17.9235
– ident: R1577CIHBADHE
  doi: 10.1007/BF00428897
– ident: R1577CIHFJCCA
  doi: 10.1002/hbm.460030303
SSID ssj0000372
Score 2.0943065
Snippet OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the...
Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is...
Increased dopaminergic neutotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is...
SourceID proquest
pubmed
pascalfrancis
crossref
appi
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1108
SubjectTerms Adult
Adult and adolescent clinical studies
Amphetamine - pharmacology
Amphetamines
Benzamides - metabolism
Biological and medical sciences
Bipolar Disorder - diagnostic imaging
Bipolar Disorder - metabolism
Bipolar Disorder - physiopathology
Bipolar disorders
Blood Pressure - drug effects
Brain
Brain - diagnostic imaging
Brain - metabolism
Brain - physiopathology
Corpus Striatum - diagnostic imaging
Corpus Striatum - metabolism
Corpus Striatum - physiopathology
Dopamine - metabolism
Dopamine Antagonists - metabolism
Female
Heart Rate - drug effects
Humans
Iodine Radioisotopes - metabolism
Male
Manic depression
Medical imaging
Medical sciences
Mental disorders
Mood disorders
Neurotransmitters
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Pulse
Pyrrolidines - metabolism
Receptors, Dopamine - drug effects
Receptors, Dopamine - metabolism
Tomography, Emission-Computed, Single-Photon
Title Brain SPECT Imaging of Amphetamine-Induced Dopamine Release in Euthymic Bipolar Disorder Patients
URI http://dx.doi.org/10.1176/appi.ajp.157.7.1108
https://www.ncbi.nlm.nih.gov/pubmed/10873919
https://www.proquest.com/docview/1518396490
https://www.proquest.com/docview/220459437
https://www.proquest.com/docview/71222089
Volume 157
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSAgJId6EtuADF1SyZONsHB-hKiqgIqTdoopL5DgOW8QmUTd74dcz49h5wLYCLlHkiRPL35fJTOyZIeQF05HOBct9yUXgRzqc-kkhM1_luQK8VcAkxjuffIqPT6MPZ7Ozfq-qiS5pson6uTWu5H9QhTbAFaNk_wHZ7qbQAOeALxwBYTj-FcZvsb7Dwfzz0eHi4Hxl6w1hAaF6qRu5AgPSB5d7g0v8OTjH2GCKpMCXy6QK2QBKuDc-O6_Rw8XVGpOK02VbXQ9N10Ufg1IOE06M90u3vxTcbknX8kVfLCvdJoDsAsrmoGaVHC0Hfa2-LTOzv2Bu_8m6HxJBt3l1qGTFzJT57ZVsm4basokPVCbGIWzX5dwkMa4xpu97PYE7TPjk96sBkHpl4AUBZ8Lq33EKbSe6Tm6E4E0Yz_v9x_6DzXjovCQct01OBc9_veXpmGbW3g8-43jByKS5Xcs1vF1FWxblcr_F2C-Lu-SOdTzom5ZF98g1Xd4nN0_s1ooHRBoyUUMmaslEq4JuIRN1ZKKWTBQ6OjJRSybqyEQdmR6S03dHi8Nj39bf8GUkwsbPWKZEkoPTWUgWJIqHgYzDPBFaBrHIYpDrhBVwpsIcJ1YKmJhMCskl52LKHpGdsir1E0J5kcRoCapYRRHjkShC0B2iyKXSQZFMPfISZzK17F2nxjflcWpaAYAUAEh5igB4JHTTnSqbyB7rqfy4utOrrlPd5nG5-vL9EY59Hxg9zINH9hyugzHP0N2IIwHi3T_FIVZ-ENDfI887KShzXKGTpa4265RPwVwPEuGRxy1XBmNtKff0UskuudW_jXtkp7nY6H0wmJvsmaH7L4kqvzM
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brain+SPECT+imaging+of+amphetamine-induced+dopamine+release+in+euthymic+bipolar+disorder+patients&rft.jtitle=The+American+journal+of+psychiatry&rft.au=Anand%2C+A&rft.au=Verhoeff%2C+P&rft.au=Seneca%2C+N&rft.au=Zoghbi%2C+S+S&rft.date=2000-07-01&rft.issn=0002-953X&rft.volume=157&rft.issue=7&rft.spage=1108&rft_id=info:doi/10.1176%2Fappi.ajp.157.7.1108&rft_id=info%3Apmid%2F10873919&rft.externalDocID=10873919
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-953X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-953X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-953X&client=summon